3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
NIH
8
INDUSTRY
3
OTHER
2
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Dermatologic
1
Conditions
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Interventions
Magnetic Resonance Spectroscopy
81
Specimen Handling
80
Cyclophosphamide
72
pembrolizumab
61
Nivolumab
53
Radiotherapy
52
fludarabine
43
Cisplatin
42
Biopsy
40
Carboplatin
38
Standard of Care
35
Dexamethasone
31
Radiation
30
Bevacizumab
30
Rituximab
29
Surveys and Questionnaires
27
Radiosurgery
26
Doxorubicin
26
Temozolomide
25
Gemcitabine
25
Cytarabine
25
Blood Specimen Collection
25
venetoclax
24
Practice Guidelines as Topic
24
Paclitaxel
24
fludarabine phosphate
23
Ipilimumab
21
atezolizumab
20
Vincristine
20
Interviews as Topic
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
trametinib
×
30 days
×
Clear all
NCT02645149
2026-05-29
Match Mel
Melanoma Institute Australia
Phase 2
Completed
216 enrolled
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled